TKT Replagal Approval Path Will Begin With Request For Protocol Assessment
Executive Summary
Transkaryotic Therapies hopes to begin discussion on a potential approval pathway for the Fabry disease agent Replagal in November via a request for an FDA special protocol assessment, CEO Michael Astrue said during an Oct. 29 conference call